Subtotal petrosectomy may be performed for refractory chronic middle ear diseases, such as massive cholesteatoma or recurrent otitis media. It involves permanent obliteration of the operative cavity, thus precluding the chance to restore conductive hearing via traditional inertial ossicular prostheses. The Vibrant Soundbridge (VSB) is an alternative option for hearing rehabilitation. Vibrant energy is delivered into the inner ear via a floating mass transducer (FMT), which can be coupled with any part of the middle ear acoustic transmission structure. To restore the hearing of a young woman with cholesteatoma, we combined subtotal petrosectomy with obliteration of the cavity and VSB implantation with an FMT coupled to the stapes head. Two years of follow-up demonstrated excellent auditory rehabilitation, improved sound source localization ability, and a lower speech recognition threshold. This study showed that the FMT works well in an obliterated cavity, and the experience acquired through this successful exploration is worth disseminating.

Fisch U, Mattox D: Microsurgery of the Skull Base. Stuttgart, Thieme, 1988.
Fisch U, Cremers CW, Lenarz T, Weber B, Babighian G, Uziel AS, et al: Clinical experience with the Vibrant Soundbridge implant device. Otol Neurotol 2001; 22: 962–972.
Luetje CM, Brackman D, Balkany TJ, Maw, J, Baker RS, Kelsall D, et al: Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device: a prospective controlled multicenter study. Otolaryngol Head Neck Surg 2002; 126: 97–107.
Vyskocil E, Riss D, Honeder C, Arnoldner C, Hamzavi JS, Baumgartner WD, et al: Vibroplasty in mixed and conductive hearing loss: comparison of different coupling methods. Laryngoscope 2014; 124: 1436–1443.
Huber AM, Mlynski R, Muller J, Dillier N, Holzmann D, Wolframm MD, et al: A new vibroplasty coupling technique as a treatment for conductive and mixed hearing losses: a report of 4 cases. Otol Neurotol 2012; 33: 613–617.
Colletti V, Soli SD, Carner M, Colletti L: Treatment of mixed hearing losses via implantation of a vibratory transducer on the round window. Int J Audiol 2006; 45: 600–608.
Henseler MA, Polanski JF, Schlegel C, Linder T: Active middle ear implants in patients undergoing subtotal petrosectomy: long-term follow-up. Otol Neurotol 2014; 35: 437–441.
Linder T, Schlegel C, DeMin N, van der Westhuizen S: Active middle ear implants in patients undergoing subtotal petrosectomy: new application for the Vibrant Soundbridge device and its implication for lateral cranium base surgery. Otol Neurotol 2009; 30: 41–47.
Hartmann WM: Localization of sound in rooms. J Acoust Soc Am 1983; 74: 1380–1391.
Wong LL, Soli SD, Liu S, et al: Development of the Mandarin Hearing in Noise Test (MHINT). Ear Hear 2007; 28: 70S–74S.
Chen T, Ren LJ, Yin DM, Li J,Yang L, Dai PD, et al: A comparative study of MED-EL FMT attachment to the long process of the incus in intact middle ears and its attachment to disarticulated stapes head. Hear Res 2017; 353: 97–103.
Wagner F, Todt I, Wagner J, Ernst A: Indications and candidacy for active middle ear implants. Adv Otorhinolaryngol 2010; 69: 20–26.
Mlynski R, Dalhoff E, Heyd A, Wildenstein D, Hagen R, Gummer AW, et al: Reinforced active middle ear implant fixation in incus vibroplasty. Ear Hear 2015; 36: 72–81.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.